Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.

[1]  O. Van Der Meeren,et al.  A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults , 2015, Human vaccines & immunotherapeutics.

[2]  O. Van Der Meeren,et al.  Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis , 2015, Human vaccines & immunotherapeutics.

[3]  A. Kilcoyne,et al.  Clinical study report , 2013 .

[4]  C. Weyand,et al.  Understanding immunosenescence to improve responses to vaccines , 2013, Nature Immunology.

[5]  M. Kundi,et al.  Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. , 2013, Vaccine.

[6]  L. Rombo,et al.  Immunogenicity of delayed TBE-vaccine booster. , 2012, Vaccine.

[7]  S. Dewasthaly,et al.  Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®). , 2011, Vaccine.

[8]  S. Hills,et al.  Estimated global incidence of Japanese encephalitis: a systematic review. , 2011, Bulletin of the World Health Organization.

[9]  D. Vaughn,et al.  Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study , 2011, The Journal of infectious diseases.

[10]  B. Jilma,et al.  Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. , 2010, Vaccine.

[11]  S. Hills,et al.  Japanese encephalitis in travelers from non-endemic countries, 1973-2008. , 2010, The American journal of tropical medicine and hygiene.

[12]  J. Skorkovský,et al.  Serological response to tick-borne encephalitis (TBE) vaccination in the elderly – results from an observational study , 2009, Expert opinion on biological therapy.

[13]  J. Utzinger,et al.  Past, Present, and Future of Japanese Encephalitis , 2009, Emerging infectious diseases.

[14]  F. Heinz,et al.  Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. , 2008, Vaccine.

[15]  W. J. McBride,et al.  Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. , 2008, The Journal of infectious diseases.

[16]  C. Klade,et al.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial , 2007, The Lancet.

[17]  T. Solomon.  Control of Japanese encephalitis--within our grasp? , 2006, The New England journal of medicine.

[18]  B. Genton,et al.  Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. , 2006, Journal of travel medicine.

[19]  I. Kurane,et al.  Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. , 2005, Vaccine.

[20]  A. Barrett,et al.  Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. , 2005, Vaccine.

[21]  M. Roggendorf,et al.  Immunogenicity of combined hepatitis A and B vaccine in elderly persons. , 2003, Vaccine.

[22]  S. Ritchie,et al.  Ecology and geographical expansion of Japanese encephalitis virus. , 2009, Annual review of entomology.

[23]  D. Vaughn,et al.  The epidemiology of Japanese encephalitis: prospects for prevention. , 1992, Epidemiologic reviews.